KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.

A Gravina, P Gargiulo, M De Laurentiis, L Arenare, S De Placido, M Orditura, S Cinieri, F Riccardi, A S Ribecco, C Putzu, L Del Mastro, E Rossi, F Ciardiello, F Di Rella, F Nuzzo, C Pacilio, R Caputo, D Cianniello, V Forestieri, M Giuliano, G Arpino, L Orlando, C Mocerino, C Schettino, M C Piccirillo, C Gallo, F Perrone

ESMO Open 10(1) 104085

PMID39754976
PMCIDPMC11758124
DOI10.1016/j.esmoop.2024.104085
发表日期2025-01-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The Hormonal Bone Effects (HOBOE) study tested whether adjuvant triptorelin plus either letrozole (L) or zoledronic acid (Z) plus L (ZL) was more effective than tamoxifen (T) in premenopausal patients with hormone receptor-positive (HR+) early breast cancer (BC). Here we report the long-term follow-up analysis. PATIENTS AND METHODS: HOBOE (ClinicalTrials.gov number NCT00412022) is an open-label, three-arm, randomised, phase III trial that involved 16 centres in Italy. One thousand and sixty-five premenopausal patients with HR+ early BC receiving triptorelin were randomly assigned (1 : 1 : 1) to adjuvant T, L or ZL for 5 years. Cancer recurrence, second breast or non-breast cancer and death were considered events for the intention-to-treat disease-free survival (DFS) analysis. RESULTS: As of 24 October 2024 at a median follow-up of 9.2 years, 199 DFS events and 79 deaths were reported. Both ZL and L improved DFS over T, with a hazard ratio (HR) of 0.58 [95% confidence interval (CI) 0.41-0.82; P = 0.002] for ZL versus T and 0.69 (95% CI 0.49-0.97, P = 0.030) for L versus T. No statistically significant difference in OS was reported (global log-rank P = 0.103). The previously reported statistically significant interaction with human epidermal growth factor receptor 2 (HER2) status was confirmed for ZL versus T comparison (P = 0.007). CONCLUSION: In this updated analysis, L plus triptorelin, with or without Z, demonstrated a statistically significant DFS improvement over T plus triptorelin for the adjuvant treatment of early BC in premenopausal patients.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Kaplan–Meier estimated curves of DFS. (A) and OS (B) by treatment arm. DFS, disease-free survival; L, letrozole; OS, overall survival; T, tamoxifen; ZL, zoledronic acid plus letrozole.

A

DFS

Figure 1 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

OS

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Kaplan–Meier estimated curves of DFS. (A) HER2-negative and (B) HER2-positive patients by treatment arm. DFS, disease-free survival; T, tamoxifen; ZL, zoledronic acid plus letrozole.
非 KM Figure